SCHEMBL16112334

SCHEMBL16112334

COc1cccc(C=O)c1OC(=O)Oc1c(C=O)cccc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.62
TLR2 O60603 1/20 0.59
ERN1 O75460 1/20 0.59
TLR1 Q15399 1/20 0.59
TLR6 Q9Y2C9 1/20 0.59
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
NFE2L2 Q16236 3/20 0.53
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
HPGD P15428 1/20 0.48
ALDH1A1 P00352 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TFEB P19484 1/20 0.45
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665129 0.93 SRC (0.59) SRCTLR2ERN1TLR1TLR6
SCHEMBL807200 0.88 TLR2 (0.62) SRCTLR2ERN1TLR1TLR6
SCHEMBL16048364 0.88 SRC (0.60) SRCTLR2ERN1TLR1TLR6
SCHEMBL16072692 0.88 SRC (0.54) SRCTLR2ERN1TLR1TLR6
SCHEMBL4645064 0.87 SRC (0.59) SRCTLR2ERN1TLR1TLR6
SCHEMBL4642146 0.85 SRC (0.57) SRCTLR2ERN1TLR1TLR6
SCHEMBL24810562 0.84 SRC (0.56) SRCTLR2ERN1TLR1TLR6
SCHEMBL4645165 0.84 SRC (0.56) SRCTLR2ERN1TLR1TLR6
SCHEMBL3308881 0.84 SRC (0.56) SRCTLR2ERN1TLR1TLR6
O-Veratraldehyde SCHEMBL29923149 0.83 SRC (0.67) SRCTLR2ERN1TLR1TLR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920029-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-03-20 US disclosed
EP-2970183-A2 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS Musc Foundation for Research Development (US) 2016-01-20 EP disclosed
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders MUSC Foundation for Research Development (10 pp.) 2015-08-06 US disclosed
WO-2014160143-A2 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders CLN6, AREG, HASPIN SRC 3730/4885TLR2 4421/4885ERN1 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.